Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients

Journal of the American Pharmacists Association : JAPhA
Bethany A DiPaula, Elizabeth Menachery

Abstract

To develop a physician-pharmacist collaborative practice for opioid-dependent patients designed to increase access to treatment, optimize patient care, reduce cost, minimize physician burden, and prevent diversion. Suburban health department. Physician-pharmacist buprenorphine/naloxone maintenance practice. Traditionally, health department buprenorphine/naloxone patients have been referred to community physicians at considerable cost with varying outcomes. In this pilot project, patients were managed using a drug therapy management model. Intake assessments and follow-up appointments were conducted by the pharmacist. The pharmacist debriefed with the physician and documented each interaction, allowing for efficient assessment completion. The physician appended notes, when applicable, and cosigned each patient's record. The pharmacist prevented diversion by gathering data from outside providers, pharmacies, and laboratories. This health department program improved care by producing structure and expanding treatment options. A total of 12 patients completed full intakes with 135 follow-up appointments equating to an estimated savings of $22,000. The program demonstrated a 91% attendance rate, 100% 6-month retention rate, and 73% ...Continue Reading

References

Feb 9, 2002·Journal of the American Pharmaceutical Association : APhA·Dara C Bultman, Bonnie L Svarstad
May 4, 2004·General Hospital Psychiatry·Kathleen M BungayIra B Wilson
Nov 26, 2005·Journal of General Internal Medicine·Michael D SteinPeter D Friedmann
Mar 29, 2007·Annals of Family Medicine·Ira L MintzerSteffie Woolhandler
Jun 28, 2007·Journal of Addictive Diseases·Stephen MaguraAndrew Rosenblum
Jan 5, 2008·Mayo Clinic Proceedings·Karen E MoellerJulie C Kissack
Apr 9, 2008·The American Journal on Addictions·David A FiellinRichard S Schottenfeld
May 7, 2008·Annals of Internal Medicine·Lynn E Sullivan, David A Fiellin
Jul 2, 2008·Journal of General Internal Medicine·Alexander Y WalleyDaniel P Alford
Aug 22, 2008·Journal of Substance Abuse Treatment·Julie NetherlandUNKNOWN BHIVES Collaborative
Dec 18, 2008·Journal of General Internal Medicine·Joshua D LeeMarc N Gourevitch
Jun 26, 2009·Journal of Substance Abuse Treatment·Janet M SoeffingDarius A Rastegar
Sep 1, 2009·Drug and Alcohol Dependence·T V ParranA G Mace
Oct 6, 2009·Journal of Substance Abuse Treatment·Nancy L SohlerChinazo O Cunningham
Jul 6, 2010·Journal of Substance Abuse Treatment·Cynthia L ArfkenCharles Roberts Schuster
Oct 14, 2010·JAMA : the Journal of the American Medical Association·Patrick G O'Connor
Feb 9, 2011·American Journal of Pharmaceutical Education·Steven C StonerBethany A Dipaula
Nov 2, 2011·Journal of Addiction Medicine·Mark L KrausUNKNOWN American Society Of Addiction Medicine
Nov 23, 2011·Journal of Addiction Medicine·Karen MiottoWalter Ling
Mar 28, 2012·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN Centers for Disease Control and Prevention, Public Health Service, U.S. Department Health
Feb 21, 2013·JAMA : the Journal of the American Medical Association·Christopher M JonesLeonard J Paulozzi
Sep 18, 2013·Annals of Internal Medicine·Robert B DohertyUNKNOWN Health and Public Policy Committee of the American College of Physicians
Nov 22, 2013·Journal of the American Pharmacists Association : JAPhA
Dec 7, 2013·International Journal of Clinical Pharmacy·Tom E RichardsonTimothy F Chen
Jan 15, 2014·Hospital Pharmacy·Allison R King, UNKNOWN University of Kansas Drug Information Center Experiential Rotation Students, August 2012
Mar 13, 2014·Annals of Family Medicine·Eliza HutchinsonRoger A Rosenblatt

❮ Previous
Next ❯

Citations

May 21, 2016·Thérapie·François EtcheverrigarayCaroline Victorri-Vigneau
Mar 16, 2017·Journal of the American Pharmacists Association : JAPhA·Jeffrey P Bratberg
Aug 11, 2018·Journal of Addiction Medicine·Shannon Gwin MitchellRobert P Schwartz
Dec 7, 2019·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Jeffrey Bratberg
Oct 9, 2019·Substance Use & Misuse·Daniel J VentricelliNicholas E Hagemeier
Apr 22, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Pooja LagisettyMichele Heisler
Dec 17, 2020·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Beth M DeRonneErin E Krebs
Jul 23, 2019·Research in Social & Administrative Pharmacy : RSAP·Lauren HaslamAndrea Lynn Murphy
Nov 24, 2020·The Mental Health Clinician·Amy WerremeyerJerry McKee
Feb 23, 2021·Journal of Substance Abuse Treatment·Asif KhanElizabeth Kolb
May 28, 2021·British Journal of Clinical Pharmacology·Margaret JordanTimothy F Chen
Jul 17, 2021·Journal of the American Pharmacists Association : JAPhA·Elizabeth Chiarello
Aug 7, 2021·The International Journal on Drug Policy·Phillip L MarottaLouisa Gilbert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.